To Engineer Recovery, Sinobiomed’s New American Leaders Seek Licensing Deals, Strategic Investment From Global Pharma
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Aiming to reverse a 97.5 percent decline in the company's valuation over the past two years, the board of directors of Sinobiomed has appointed a team of American executives charged with engineering a recovery
You may also be interested in...
Venture Capitalists Freeze Funding For Some U.S. Start-ups, But Could Channel More Investment Into China Health Care
BEIJING - While the Western world's financial maelstrom is already choking off funding for some biotech start-ups in the U.S., it could have the opposite effect in China, and trigger the flow of more capital into promising Chinese healthcare outfits, according to a partner in a half-billion-dollar venture capital firm
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).